Advertisement
Advertisement
U.S. Markets close in 1 hr
Advertisement
Advertisement
Advertisement
Advertisement

Novo Nordisk A/S (NVO)

NYSE - Nasdaq Real Time Price. Currency in USD
139.14+1.07 (+0.77%)
As of 03:00PM EST. Market open.
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close138.07
Open138.33
Bid138.89 x 900
Ask138.97 x 800
Day's Range138.15 - 139.15
52 Week Range94.75 - 144.78
Volume722,487
Avg. Volume1,449,960
Market Cap312.838B
Beta (5Y Monthly)0.31
PE Ratio (TTM)47.65
EPS (TTM)2.92
Earnings DateN/A
Forward Dividend & Yield1.60 (1.48%)
Ex-Dividend DateAug 12, 2022
1y Target Est128.29
  • GlobeNewswire

    Novo Nordisk A/S - share repurchase programme

    Bagsværd, Denmark, 07 February 2023 – On 1 February 2023, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 28 billion to be executed during a 12-month period beginning 1 February 2023. Under the programm

  • GlobeNewswire

    Novo Nordisk A/S: Trading in Novo Nordisk shares by board members, executives and associated persons

    Bagsværd, Denmark, 7 February 2023 — This company announcement discloses the data of the transaction(s) made in Novo Nordisk shares by the company’s board members, executives and their associated persons in accordance with Article 19 of Regulation No. 596/2014 on market abuse. The company’s board members, executives and their associated persons have given Novo Nordisk power of attorney on their behalf to publish trading in Novo Nordisk shares by the company’s board members, executives and their

  • Zacks

    Gilead (GILD) Q4 Earnings & Sales Top on Biktarvy & Oncology

    Gilead's (GILD) Q4 earnings and sales beat on strong HIV and oncology business. The guidance for 2023 was also ahead of expectations.

Advertisement
Advertisement